The cannabis industry continues to deliver storylines, both negative and positive, that leave investors scratching their heads about which pot stocks to buy. One recent story has shined a light on Hexo (NYSE:HEXO), which could end up hurting Hexo stock holders. 

The debt/EBITDA is a solvency ratio that measures the amount of income a company generates that it can use to pay down its debt before accounting for interest, taxes, depreciation, and amortization expenses.

In essence, a company with a lower debt/EBITDA is more capable of paying off its debts. Today we have identified four Canadian marijuana stocks that have >$100M in debt with a low debt/EBITDA ratio relative to peers.

Teens and young adults who use electronic cigarettes are significantly more likely to use cannabis as well, according to a new study co-authored by a Canadian researcher.

Pediatrician Nicholas Chadi's analysis of previous research, published in JAMA Pediatrics, found that the likelihood of marijuana use was three to four times higher among youth who vaped.

One of the key findings showed the risk for younger adolescents aged 12 to 17 was higher than for young adults aged 18 to 24 years.

"It's an important discovery for us," said Chadi, who is now based at Montreal's Ste-Justine Hospital but conducted the research during a previous posting in Boston.

Is the marijuana stock bubble about to burst or has it just done so?

A series of unfortunate events has bruised the image of the cannabis industry. There is too much drama coming from the perceived industry leader Canopy Growth down to the second-tier cannabis companies — and stock prices for weed have fallen sharply.

Unless you’ve been living under a rock, you might have noticed that marijuana stocks have been all the rage lately. One of the larger cannabis players, Aphria (TSX:APHA)(NYSE:APHA), recently released its earnings report. Pay attention, as the earnings report was a pleasant surprise for many investors.

While THC-based foods and edibles present all sorts of challenges (mostly of health and legal nature), CBD (cannabidiol), which has no psychotropic effects, appears set to become the next miracle ingredient, according to many in the food industry.

Opiates killed 47,600 people in 2017 in the United States, according to the Centers for Disease Control (CDC). That year, the epidemic was declared a “public health emergency” by President Donald Trump.

Shares of leading cannabis company CannTrust (TSX:TRST)(NYSE:CTST) rose 40.8% on Friday. The stock is currently trading at $4.21 per share as of writing. CannTrust has taken investors on a roller-coaster ride. Company shares first declined close to 80% from $13.45 in March 2019 to $2.99 on August 7, 2019. It fell over 50% in July 2019 and has returned -57% since its IPO in January 2018.

Canopy Growth (TSX:WEED)(NYSE:CGC) is back in the headlines once again, but this time the news is of a more positive tone. The pot grower will be snapping up Beckley Canopy Therapeutics, bringing the medical research operation fully under the Canopy Growth umbrella. This encouraging business combination deal will see the Spectrum Therapeutics brand further incorporated and will support its commercial activities across its active territories.

Eating raw cannabis has been a thing for some time now, but what about eating cannabis seeds?

Munching on these crunchy bits could be a new health trend, but before cracking open a pricey bag, consider if pot or hemp seeds are the best choice for you and what you’re hoping to achieve.

Health Canada has found fault with cannabis production at a second CannTrust Holdings Inc facility, a month after the regulator froze sales of several tonnes of marijuana grown at another one of its Ontario operations.

U.S.-listed shares of the Canadian grower, down 36 per cent in the past month after it suspended sales, fired its chief executive officer, disclosed a formal investigation by local regulators and said its results may have to be restated, fell another 26 per cent in early trading to $2.30.

CannTrust said it had accepted the latest findings from the health regulator into the Vaughan facility in Ontario, which received a non-compliant rating, and expects to propose a remediation plan to Health Canada.